ClinicalTrials.gg
RecruitingNCT07395973Updated Feb 9, 2026

The Effects of a 4-week Supplementation With a Ketogenic Nutrient Mix on 24-hour Substrate Metabolism and Muscle Health

An interventional study of ketogenic nutritional Supplement and non-ketogenic, isocaloric control in Overweight and Obesity, sponsored by Maastricht University Medical Center. Recruiting at 1 site in Netherlands. Open to participants aged 60 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-09.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Maastricht University Medical Center · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
60 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 75 studies in Obesity by Maastricht University Medical Center — 4 open to participants now, 4 under way, none of them phase 3. Obesity · Maastricht University Medical Center.

Planned enrollment
58th of 67
14 · median 40
Started
2025
with 1 other
No phase
65 of 75
4 open now
Registered
73rd of 75
by date

Among the 75 studies in Obesity by Maastricht University Medical Center, this one is the 58th largest by planned enrollment of the 67 interventional ones that give a count, is one of 2 that started in 2025, is one of 65 with no phase, and was the 73rd registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

4 of the 75 studies in Obesity by Maastricht University Medical Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 60 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Obesity by Maastricht University Medical Center, or all of them as a file.
02

Study summary

This study will investigate the effect of providing a daily ketogenic nutritional supplement in the evening for a prolonged time (4 weeks) to induce a mild ketogenic state during the night in healthy elderly (60-80 years), overweight/obese (BMI: 25-35 kg/m2) individuals with low physical activity, on 24h rhythmicity in energy metabolism as compared to a non-ketogenic, isocaloric control.

03

Conditions studied

  • Overweight and Obesity

Browse trials for

04

In context

Obesity Reclassified

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

This study's planned enrollment of 14 is below the median of 67 across 9,043 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Maastricht University Medical Center is the lead sponsor of 854 studies on the registry; 114 are open to participants now.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
60 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 60-80 years
  • (BMI) 25-35 kg/m2
  • Sedentary lifestyle (not more than 2 hours of structured physical activity per week in the past 3 months)
  • Stable dietary habits (no weight loss or gain > 5 kg in the past 3 months)
  • Healthy (as determined by dependent physician based on medical questionnaire)
  • Regular sleeping habits (7-9h of daily sleep)

Exclusion criteria

Exclusion Criteria:

  • Type 2 diabetes
  • Participants with active congestive heart failure and/or severe renal and or liver insufficiency
  • Uncontrolled hypertension
  • Alcohol consumption of >3 servings per day for men and >2 servings per day for women
  • Unstable body weight (weight gain or loss > 5 kg in the last 3 months) or intention to lose weight
  • Participants who are on an intermittent fasting diet
  • Previous enrolment in a clinical study with an product during the last 3 months or as judged by the investigator which would possibly hamper our study results
  • Significant food allergies/intolerance (seriously hampering study meals or study product)
  • Participants who do not want to be informed about unexpected medical findings
  • Blood donation during or within 2 months prior to the study
  • Disturbances in circadian rhythm determined with the follow criteria:
  • Extreme early bird or extreme night person (score ≤30 or ≥70 on MEQ-SA questionnaire)
  • Heavily varying sleep-wake rhythm
  • Night shift work during last 3 months
  • Travel across > 1 time zone in the last 3 months
  • High daily caffeine intake > 400mg (more than 4 cups of coffee or energy drinks)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
14 participants (estimated)

Study arms

  • Experimental
    Ketogenic nutritional supplement

    Daily ketogenic nutritional supplement for 4 weeks

    Dietary Supplement: ketogenic nutritional Supplement

  • Placebo comparator
    non-ketogenic, isocaloric control

    Daily control for 4 weeks

    Dietary Supplement: non-ketogenic, isocaloric control

Interventions

  • Dietary supplementketogenic nutritional Supplement

    Daily ketogenic nutritional supplement for 4 weeks

  • Dietary supplementnon-ketogenic, isocaloric control

    Daily control for 4 weeks

07

What researchers measure

Primary outcomes

  1. Delta respiratory exchange ratio (from 23:00 till 04:00)

    Measured with indirect calorimetry

    Time frame: Measured after 4 weeks of daily supplementation with a ketogenic nutritional supplement or non-ketogenic, isocaloric control

Secondary outcomes

  1. Skeletal mitochondrial function

    Measured in muscle biopsy

    Time frame: Measured after 4 weeks of daily supplementation with a ketogenic nutritional supplement or non-ketogenic, isocaloric control

Other outcomes

  1. Protein and gene markers of skeletal muscle metabolism

    Measured in muscle biopsy

    Time frame: Measured after 4 weeks of daily supplementation with a ketogenic nutritional supplement or non-ketogenic, isocaloric control

  2. Metabolic blood markers

    Measured in blood samples

    Time frame: Measured after 4 weeks of daily supplementation with a ketogenic nutritional supplement or non-ketogenic, isocaloric control

  3. Interstitial ketone levels

    Measured with a continuous ketone monitor

    Time frame: Measured after 4 weeks of daily supplementation with a ketogenic nutritional supplement or non-ketogenic, isocaloric control

  4. Interstitial glucose levels

    Measured with a continuous glucose monitor

    Time frame: Measured after 4 weeks of daily supplementation with a ketogenic nutritional supplement or non-ketogenic, isocaloric control

  5. Whole body substrate utilization

    Measured with indirect calorimetry

    Time frame: Measured after 4 weeks of daily supplementation with a ketogenic nutritional supplement or non-ketogenic, isocaloric control

  6. Whole body energy expenditure

    Measured with indirect calorimetry

    Time frame: Measured after 4 weeks of daily supplementation with a ketogenic nutritional supplement or non-ketogenic, isocaloric control

  7. Physical performances

    Measured with 6-minute walk test, chair-stand-test, and handgrip strength test

    Time frame: Measured after 4 weeks of daily supplementation with a ketogenic nutritional supplement or non-ketogenic, isocaloric control

  8. Cognitive performance

    Measured using Cambridge Neuropsychological Test Automated Battery (CANTAB) and cerebral perfusion measured with transcranial doppler ultrasound

    Time frame: Measured after 4 weeks of daily supplementation with a ketogenic nutritional supplement or non-ketogenic, isocaloric control

  9. Other perceivable benefits: microvasculature

    Measured with retinal images

    Time frame: Measured after 4 weeks of daily supplementation with a ketogenic nutritional supplement or non-ketogenic, isocaloric control

  10. Other perceivable benefits: sleep quality

    Measured with sleep quality questionnaires

    Time frame: Measured after 4 weeks of daily supplementation with a ketogenic nutritional supplement or non-ketogenic, isocaloric control

  11. Body composition

    Measured with BodPod

    Time frame: Measured after 4 weeks of daily supplementation with a ketogenic nutritional supplement or non-ketogenic, isocaloric control

08

Study locations

1 of 1 sites recruiting
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Oct 2027, 23 months after the start.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 23 months is close to that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2025
First posted
Feb 9, 2026
StartActual
Nov 25, 2025
Primary completionEst.
Oct 31, 2027
CompletionEst.
Oct 31, 2027
Last update
Feb 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07395973
Responsible party
Sponsor
First posted
Feb 9, 2026
Start date
Nov 25, 2025
Primary completion
Oct 31, 2027 (estimated)
Completion
Oct 31, 2027 (estimated)
Last update
Feb 9, 2026

Study contacts

Merel Timmermans, MSc
Contact
merel.timmermans@maastrichtuniversity.nl
0031 88 3887793
Joris Hoeks, Dr.
Contact
Joris Hoeks, Dr.
principal investigator · Maastricht University
Peter Joris, Dr.
principal investigator · Maastricht University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion